Zacks Investment Research on MSN
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
Intellia Therapeutics NTLA has made meaningful progress with the development of its in vivo programs. The company is currently advancing two late-stage in vivo candidates — lonvo-z (or, NTLA-2002) for ...
Importantly, the researchers at Boston Children's Hospital utilized the Nabsys OhmX Platform to identify a ...
Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug ...
BRENTFORD, ENGLAND, UNITED KINGDOM, October 14, 2025 / EINPresswire.com / -- The global CRISPR gene-editing market is expected to witness significant growth, projected to rise from a valuation of US$ ...
This is a preview. Log in through your library . Abstract CRISPR/Cas9 technology has immense power to reproduce plants with desired characters and revolutionizing the field of genome engineering by ...
Cassava (Manihot esculenta Crantz, 2n = 36) is one of the most important root crops globally, particularly in tropical regions of Africa, Asia, and Latin America. It is a major source of food, ...
Artificial intelligence (AI) is known for enabling deeper insights into drug development, identifying patterns and molecules that may otherwise go unnoticed. Now it is poised to make similar ...
Kansas State University researchers and the state’s farmers are putting their collective support behind a project to reduce ...
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...
The search for gene therapies to treat rheumatoid arthritis (RA) has moved in fits and starts over the past two decades, with trials starting and stopping, and their focus shifting to osteoarthritis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results